Outcomes

The evidence for measurable outcomes from NAD+ IV infusion is extremely limited, with only one small pilot study directly examining this intervention.

Direct NAD+ IV Infusion Evidence:

A pilot study (PMID: 31572171) investigated changes in plasma and urine NAD+ metabolites during a 6-hour intravenous NAD+ infusion. This study appears to focus primarily on metabolomic changes rather than clinical outcomes, though specific measurable results are not detailed in the available evidence.

A retrospective tolerability study (PMID: 41704678) compared IV NAD+ infusion to nicotinamide riboside supplementation in a real-world setting, but this study focused on safety and tolerability rather than efficacy outcomes.

Indirect Evidence from Related NAD+ Research:

The broader literature on NAD+ supplementation includes a systematic review (PMID: 41655607) examining preclinical and clinical evidence for anti-aging and wellness applications, though this covers various forms of NAD+ supplementation, not specifically IV infusion.

One study (PMID: 34948019) examined nicotinamide mononucleotide (a NAD+ precursor) and found it prevented free fatty acid-induced reduction in glucose tolerance by decreasing insulin clearance, but this involved oral supplementation, not IV NAD+.

Evidence Limitations:

The current evidence base for NAD+ IV infusion outcomes is notably thin. The available studies are small pilot investigations or retrospective analyses rather than controlled trials demonstrating clinical efficacy. No robust clinical trial data specifically measuring therapeutic outcomes from NAD+ IV infusion were identified in the provided evidence.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any experimental treatments.

NAD+ IV Infusion

Member access required